Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy in unresectable advanced recurrent or metastatic esophageal squamous cell carcinoma
CTR20171227Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab, ipilimumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Bristol Myers Squibb. Started Apr 2018; status: active.
02
Drugs
nivolumabipilimumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20171227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171227.